Outpost Medicine has named Ian Mills chief medical officer. Mills comes to Indianapolis-based Outpost from Mitsubishi Tanabe Pharma Europe, where he was head of clinical development. Before Mitsubishi, Mill spent 15 years at Pfizer (NYSE: [[ticker:PFE]]) in various roles. Outpost’s lead drug candidate, OP-687, is a treatment for overactive bladder and irritable bowel syndrome.
Mills is the latest addition to Outpost’s C-suite. Last month, the company named Scott Byrd president and CEO, succeeding interim CEO and co-founder David Socks, who remains on the company’s board of directors. Byrd most recently served as president and chief operating officer of Acacia Pharma.
